Asset Value Investors Limited Raises Stake in Wakamoто Pharmaceutical (4512) to 11.64% | Large Shareholding Report

A large shareholding report (EDINET filing) shows that Asset Value Investors Limited has raised its stake in Wakamoто Pharmaceutical (4512) to 11.64%. This acquisition was made by an engaged value investment firm based in the United Kingdom. Wakamoто Pharmaceutical engages in research and development, manufacturing, and sales of lactic acid bacteria preparations, supplements, and pharmaceuticals, with the investor's 11.64% stake representing a significant position in the company's equity market capitalization.

This acquisition reflects a phased approach rather than a single transaction. Asset Value Investors Limited made its initial disclosure on January 9, 2026, when it held 10.6% of the company. Over approximately seven months, the investor accumulated shares to reach the current 11.64% stake, an increase of 1.04 percentage points.

The investor's portfolio spans multiple sectors with notably high ownership positions. Holdings include Broad Media (4347, Services, 38.01%), Asiro (7378, Services, 35.23%), Atsugi (3529, Textiles, 28.47%), Sharing Technology (3989, Information & Communications, 28.18%), and Syncro Food (3963, Information & Communications, 27.68%). The 11.64% stake in Wakamoто Pharmaceutical sits at a relatively lower level within this investor's portfolio, suggesting different degrees of engagement across its holdings.

At the filing date, Wakamoто Pharmaceutical traded at ¥311 per share with a PBR of 0.93x, positioning the stock at 57% within its 52-week range (0% being the low, 100% the high). The sub-1x PBR indicates the stock is trading below book value relative to net assets. The 57% positioning in the annual trading range places the share price in the upper-middle territory, showing neither extreme weakness nor strength within the recent volatility band.

*Speculation: The phased accumulation by a UK-based engaged value investor may reflect a long-term valuation perspective on Wakamoто Pharmaceutical's business model and financial metrics.